Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | KDM6B | O15054 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131506 | 0.90 | HSD17B3 (0.40) | MCHR1HRH3HTR2CHTR2AKCNH2 | |
| SCHEMBL4148990 | 0.86 | HRH3 (0.36) | MCHR1HRH3HTR2CHTR2AKCNH2 | |
| SCHEMBL4135556 | 0.85 | CD274 (0.38) | HRH3HTR2CHTR2AKCNH2ASIC3 | |
| SCHEMBL4127461 | 0.85 | HTR2C (0.51) | HRH3HTR2CHTR2A | |
| SCHEMBL4128118 | 0.84 | PDK1 (0.42) | MCHR1HRH3HTR2CHTR2AKCNH2 | |
| SCHEMBL4127329 | 0.84 | HTR1A (0.42) | MCHR1HRH3HTR2CHTR2AKCNH2 | |
| SCHEMBL4145725 | 0.84 | HTR1A (0.44) | MCHR1OPRM1OPRK1OPRL1HTR2C | |
| SCHEMBL4142012 | 0.83 | PDK1 (0.43) | HRH3HTR2CHTR2AHSD17B3 | |
| SCHEMBL4144492 | 0.83 | HSD17B3 (0.42) | HRH3KCNH2ASIC3HSD17B3 | |
| SCHEMBL4142343 | 0.83 | HRH3 (0.40) | HRH3KCNH2ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | MCHR1 287/4885HRH3 1/4885OPRM1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.